Invention Grant
- Patent Title: Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
-
Application No.: US14892934Application Date: 2014-04-01
-
Publication No.: US09890393B2Publication Date: 2018-02-13
- Inventor: Philippe Duchateau , André Choulika , Laurent Poirot
- Applicant: Cellectis
- Applicant Address: FR Paris
- Assignee: CELLECTIS
- Current Assignee: CELLECTIS
- Current Assignee Address: FR Paris
- Agency: Arrigo, Lee & Guttman LLP
- Priority: DK201370297 20130529; DK201370771 20131213; WOPCT/EP2014/051458 20140124
- International Application: PCT/EP2014/056534 WO 20140401
- International Announcement: WO2014/191128 WO 20141204
- Main IPC: C12N15/85
- IPC: C12N15/85 ; C12N5/0783 ; C12N9/22
Abstract:
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
Public/Granted literature
- US20160272999A1 METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM Public/Granted day:2016-09-22
Information query
IPC分类:
